

## Prenatal whole exome sequencing

Quinlan-Jones, Elizabeth; Kilby, Mark; Greenfield, Sheila; Parker, Michael; McMullan, Dominic; Hurles, Matthew E; Hillman, Sarah C

DOI:

[10.1002/pd.4916](https://doi.org/10.1002/pd.4916)

License:

Other (please specify with Rights Statement)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Quinlan-Jones, E, Kilby, M, Greenfield, S, Parker, M, McMullan, D, Hurles, ME & Hillman, SC 2016, 'Prenatal whole exome sequencing: the views of clinicians, scientists, genetic counsellors and patient representatives', *Prenatal Diagnosis*. <https://doi.org/10.1002/pd.4916>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

This is the peer reviewed version of the following article: Prenatal whole exome sequencing: the views of clinicians, scientists, genetic counsellors and patient representatives, which has been published in final form at [10.1002/pd.4916](https://doi.org/10.1002/pd.4916). This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

Prenatal Whole Exome Sequencing; the Views of Clinicians, Scientists, Genetic  
Counsellors and Patient Representatives

**Elizabeth Quinlan-Jones<sup>1</sup>, Mark D. Kilby<sup>1,2,5</sup>, Sheila Greenfield<sup>3</sup>, Michael  
Parker<sup>4</sup>, Dominic McMullan<sup>6</sup>, Matthew Hurles<sup>7</sup>, Sarah Christine Hillman<sup>1,5</sup> and  
for the Prenatal Assessment of Genomes and Exomes (PAGE) Study  
Collaborative Group**

<sup>1</sup>Fetal Medicine Centre, Birmingham Women's NHS Foundation Trust, Edgbaston,  
Birmingham, B15 2TG, UK

<sup>2</sup>Birmingham Centre for Women's and New-born Health, College of Medical and  
Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

<sup>3</sup>Institute of Applied Health Research, College of Medical and Dental Sciences,  
University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

<sup>4</sup>The Ethox Centre, Nuffield Department of Population Health, University of Oxford,  
Old Road Campus, Oxford, OX3 7LF, UK

<sup>5</sup>Institute of Metabolism and Systems Research, College of Medical and Dental  
Sciences, University of Birmingham, B15 2TT, UK

<sup>6</sup>West Midlands Regional Genetics Laboratory, Birmingham Women's NHS  
Foundation Trust, Edgbaston, Birmingham, B15 2TG, UK

<sup>7</sup>Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton,  
Cambridge, CB10 1SA, UK

**Running title: Views on prenatal whole exome sequencing (WES)**

23 **Manuscript word count: 3496**

24 Corresponding author: Professor Mark D. Kilby, Birmingham Centre for Women's  
25 and New-born Health, College of Medical and Dental Sciences, University of  
26 Birmingham, Edgbaston, Birmingham, B15 2TT, UK, Tel: 0121 627 2778, Fax: 0121  
27 623 6875, Email: M.D.Kilby@Bham.ac.uk

28 **Funding**

29 The PAGE project is funded by the Wellcome Trust/Department of Health Innovation  
30 Challenge Fund (HICF – R7-396).

31 We are grateful for the participation of the following charities in this work Antenatal  
32 Results and Choices (ARC), Genetic Alliance UK, SWAN (Syndromes Without A  
33 Name) and Unique (the rare chromosome disorder support group).

34 **Conflict of interest**

35 The authors are unaware of any potential conflict of interest.

36 **What is already known about this topic?**

- 37 • Prenatal WES generates variants of uncertain significance (VUS) and  
38 incidental findings (ICFs).

39 **What does this study add?**

- 40 • Consent-takers require training.  
41 • An overview of the findings that will/won't be reported should be provided.  
42 • Patient Representative Groups (PRGs) felt women want access to all  
43 information and re-interpretation of results over time.

- Clinical Professionals (CPs) felt that interpretation should be at the point of testing only.

## **Abstract**

### **Objective**

Focus groups were conducted with individuals involved in prenatal diagnosis to determine their opinions relating to WES in fetuses with structural anomalies.

### **Method**

Five representatives of patient groups/charities (PRGs) and eight clinical professionals (CPs) participated. Three focus groups occurred (the two groups separately and then combined). Framework analysis was performed to elicit themes. A thematic coding frame was identified based on emerging themes.

### **Results**

Seven main themes (consent, analysis, interpretation/reinterpretation of results, prenatal issues, uncertainty, incidental findings, and information access) with sub-themes emerged. The main themes were raised by both groups, apart from 'analysis' which was raised by CPs only. Some subthemes were raised by PRGs and CPs (with different perspectives). Others were raised either by PRGs or CPs, showing differences in patient/clinician agendas.

### **Conclusions**

Prenatal consent for WES is not a 'perfect' process but consent takers should be fully educated regarding the test. PRGs highlighted issues involving access to results feeling that women want to know all information. PRGs also felt that patients

want re-interpretation of results over time whilst CPs felt that interpretation should be performed at the point of testing only.

**Key words:** Prenatal; genetic testing; whole exome sequencing.

## Introduction

Standard chromosome testing (G-band karyotyping) undertaken prenatally has been largely superseded by the use of chromosomal microarrays (CMAs)<sup>1</sup> identifying sub-microscopic rearrangements undetectable by conventional cytogenetic methods<sup>2</sup>. Next generation sequencing (NGS) technologies represent a further development in terms of the quantity of genetic data obtainable and the bioinformatics needed to fully utilise and interpret results<sup>3</sup>. NGS offers knowledge, but comes with challenges<sup>4</sup>. Genome wide testing produces huge quantities of information, some of which may be uncertain and/or unanticipated, raising ethical concerns about disclosure and stimulating debate regarding how best to integrate such testing into prenatal clinical practice<sup>5</sup>.

Within the postnatal/paediatric setting parents value being able to choose the types of genetic information they wish to receive and their understanding of the different options for the return of findings (and the implications of receiving different kinds of results) can be facilitated by the consent process<sup>6</sup>. Parents do not express desire to know any and all genetic findings<sup>7</sup>, rather they prefer to receive information that they consider to be actionable, allowing them to balance the possible benefits and harms of learning their children's genetic results<sup>8</sup>. Parents can sometimes find themselves

89 in uncharted territory needing to decide which types of findings (beyond primary  
90 variants) to receive<sup>7</sup>.

91 There is little guidance relating to the process and content of informed consent for  
92 whole genome sequencing (WGS) and whole exome sequencing (WES) in the  
93 prenatal setting or the means by which results should be reported back to families<sup>9</sup>.  
94 Despite uncertainties, sequencing technologies are being introduced to clinical  
95 practice and reduction in cost is focusing the need to evaluate the balance of  
96 potential benefits and harms for patients undergoing prenatal genetic diagnosis<sup>10</sup>. A  
97 significant barrier to the integration of WES/WGS into clinical care involves the  
98 management of incidental findings (results that are not related to the patient's clinical  
99 indication for testing)<sup>9</sup>. The issue is compounded by the biological time-frame of  
100 pregnancy, which creates a sense of time pressure<sup>11</sup>. It is essential that we seek to  
101 understand the impact WGS/WES (and the uncertainty associated with it) has on  
102 families, if not we risk, potentially incorrectly, assuming families are making properly  
103 informed decisions<sup>12</sup>.

104 As a first step to gain insight into the opinions of individuals with personal or  
105 professional experience of WES within the prenatal setting, focus group sessions  
106 were conducted with representatives of patient groups/charities (PRGs) that support  
107 families undergoing genetic testing and genetic diagnosis, and clinical professionals  
108 and clinical genetic scientists (CPs) involved in prenatal diagnosis to discuss the  
109 issues. The aim of the focus group sessions with PRGs and CPs reported here was  
110 to gain information to subsequently inform ethical guidance relating to prenatal  
111 genetic sequencing and to help design an interview schedule to be used to

understand the experiences of families undergoing prenatal WES as a further phase of the work.

## **Method**

To identify participants for the PRG and CP focus groups members of the Prenatal Assessment of Genomes and Exomes (PAGE) Study working group used convenience sampling<sup>13</sup> to contact individuals known to be experts in their field. Three groups were held in succession during the afternoon of 9<sup>th</sup> October 2014. The first focus group consisted of five PRGs from the charities; Antenatal Results and Choices (ARC), Genetic Alliance UK, SWAN and Unique. The second focus group consisted of eight CPs (two fetal medicine consultants, two genetic counsellors, two consultant clinical geneticists and two clinical genetic scientists). The third focus group combined all thirteen participants of the first and second focus groups. The focus groups were conducted by SH, EQJ and MP using a topic guide; the main areas covered are shown in Table 1. We held separate focus groups of PRGs and CPs first in order to allow for any topics to be discussed that might not be discussed in the presence of the other group. The third group used the same topic guide, but focused on areas that had been felt by the facilitators to be areas of differences of opinion (between the CPs and PRGs) during focus groups one and two. The size of the focus groups was limited by the number of professionals we could assimilate geographically on the same day. All participants gave written consent. Ethical approval for the focus groups was provided by the NRES Committee West Midlands –South Birmingham (14/WM/0150).

## **Analysis**

The focus groups were voice recorded and then transcribed verbatim. Data was analysed using a thematic approach<sup>14,15</sup>. To gain familiarization with the data the transcripts were read and re-read by SH and EQJ. Throughout this process key ideas and recurrent themes were noted. A coding frame was then identified based on the emerging themes. The coding frame was refined as transcripts were added. This was agreed between three authors (SH, EQJ and SG). All text was indexed numerically, with numbers placed in the margin beside the text. The original pieces of data were charted using Excel (©Microsoft Office 2010). Charts were developed using themes and subthemes.

## **Results**

The thirteen participants came from four different charities and six healthcare sites within three geographical areas of the UK (Table 2). Seven main themes with sub-themes were identified. With the exception of theme two, 'Analysis', which was raised by CPs only (FG1) all themes were discussed by both PRGs and CPs (FG1 and FG2). Within those seven main themes some similar subthemes were either a) raised by both groups (with similar or different opinions) or b) different subthemes were raised by the separate groups, showing a difference in the patient and clinician agenda (Table 3). Quotations with their focus group identifier (FG1, FG2, and FG3) are used to reflect the themes and sub-themes.

### **Theme One: Consent**



158 The first theme, consent, was discussed by PRGs and CPs. Much of the discussion  
 159 focused on the problem of consenting for a complicated test and the time/resources  
 160 that facilitating informed consent would require. In addition, the possibility of an ‘opt  
 161 in’ consent form was discussed whereby patients could give different levels of  
 162 consent depending on the results they wanted to receive.

163 Both PRGs and CPs expressed concern about how much detailed information  
 164 should be given in the consent process:

165 *CP “There seems to be a variation and divergence of opinion between clinical*  
 166 *geneticists and the clinicians that deal with the parents as to how much information*  
 167 *needs to be provided about problems that are clearly not related to the indication or*  
 168 *reason for testing and I think that is my major concern” FG2*

169 Both expressed concern about who would obtain consent and the possibility of an  
 170 ‘education gap’ if those taking consent did not have a full understanding of the  
 171 testing:

172 *PRG “Who is going to be doing all this counselling? It can’t possibly be Geneticists,*  
 173 *it’s going to be non-genetics professionals and I think there is a huge education gap*  
 174 *there which needs filling” FG1*

175 Both also expressed concern about adding pressure to ‘overstretched services’ and  
 176 the time it would take to consent for prenatal WES given the scope of what it could  
 177 report:

178 *PRG “I think there is a worry too about the pressure it puts on genetics, pressure on*  
 179 *genetic counsellors, because it is all, certainly in the first instance, going to be*  
 180 *focused on them and they are already stretched” FG1*

181 Finally both PRGs and CPs discussed the option of an ‘opt in’ consent form whereby  
 182 patients could choose to receive findings of incidental significance in addition to  
 183 results relating to the primary reason for testing. PRGs felt this was something  
 184 patients would welcome. CPs however felt that this type of consent would need to  
 185 be taken by a clinical geneticist or genetics counsellor.

186 An area discussed by PRGs only was motivation for testing. PRGs felt the most  
 187 common motivation for testing was reassurance. Other motivators were recurrence  
 188 risk, ‘for extra information’ and wanting a genetically perfect baby:

189 *PRG “maybe there would be pressure for people to make sure their baby is*  
 190 *perfect...it is a bit of a nightmare really” FG1*

## 191 **Theme Two: Analysis**

192 This theme was only discussed by the CP group. This is not surprising given that  
 193 the CP group contained clinical scientists. The potential to ‘target’ the testing to  
 194 relevant genes was discussed. It was felt this would negate the problem of  
 195 incidental findings but in practice would be difficult to achieve given the current limits  
 196 of genetic knowledge:

197 *CP “I kind of assume that you are going to do a target interpretation of that data and*  
 198 *what you target is going to affect how you consent so if you are not going to look at*  
 199 *BRCA1 and BRCA2 then you don’t need to consent about it” FG2*

## 200 **Theme Three: Interpretation/reinterpretation of results**

201 Although this was discussed by both PRGs and CPs, there was a difference of  
 202 opinion between the groups regarding reinterpretation of results over time. CPs felt

203 results should be reviewed at the time of testing only. PRGs felt that patients would  
204 want information as and whenever it became available:

205 *PRG “Our families that we support, they live without knowing for years and years,*  
206 *some of them, and their need for that diagnosis never goes away...if something five*  
207 *years down the line came up and suddenly they could link that then those families*  
208 *would most definitely want to know” FG3*

209 *CP “it is a unique situation in medicine where we might have to reinterpret a test that*  
210 *was done for an entirely different reason five years ago in the context of what is*  
211 *known now...if the mother or father had not reported it [a medical concern] and the*  
212 *child hasn’t been presented to a medical practitioner, do we have a right to go along*  
213 *[contact the family] and say okay we found this relationship [genetic variation] exists*  
214 *and disrupt this family when they have perceived no medical problem at all?” FG3*

215 Only PRGs discussed access to the generated genetic data:

216 *PRG “a high percentage of families said if you had knowledge about me, my child or*  
217 *my baby, that is my knowledge and I want it, even to the point of wanting the raw*  
218 *sequencing data” FG1*

219 PRGs felt that women and their families wanted ‘all’ the information possible but that  
220 when the test became a reality fewer may choose to receive results of uncertain  
221 significance or incidental findings:

222 *PRG “Experience from when the Huntington’s test was made available on the NHS*  
223 *was that the community wanted it and everyone would go for it and then in practice I*  
224 *think it’s about a third go for it...we think maybe this (WES) is the same thing again”*  
225 *FG1*

## 226 **Theme Four: Issues specific to prenatal WES**

227 The reasons that prenatal exome sequencing is different from postnatal sequencing  
228 were explored by both PRGs and CPs. Both agreed that pregnancy is a uniquely  
229 stressful situation with a 'biological timeframe':

230 *PRG "Your mind is jelly. It takes you weeks to get your mind working properly, even*  
231 *if you are in the business, so God help people who have not even got the basic*  
232 *knowledge of what genetic testing is and what it means" FG1*

233 The PRGs alone discussed non-agreement between partners. They also discussed  
234 the difficulties that couples have prenatally making an 'imaginary leap' as to what  
235 they would do with results:

236 *PRG "a lot of people they will nod their heads and make the right noises but they*  
237 *might not have thought the consequences through and they are the ones when*  
238 *something anomalous is picked up who will need the most time and concentration in*  
239 *helping them to work out what the result means to them" FG1*

240 The CPs group raised the issue that there is a more ambiguous phenotype  
241 antenatally, for instance you cannot see neurodevelopment, and this is an obvious  
242 limitation to counselling.

## 243 **Theme Five: Uncertainty**

244 There is often uncertainty in prenatal counselling for structural fetal anomalies as the  
245 full phenotype may not be detectable on scan and a genetic diagnosis maybe  
246 associated with variable penetrance. Additionally WES detects variants where there  
247 is not enough definitive information to say that the genetic difference is the cause of

248 the scan findings. These variants of uncertain significance (VUS) present difficulties  
 249 in the counselling of women if they are reported.

250 Both the CPs and PRGs agreed that reporting VUS to patients can have a negative  
 251 impact on the patient and potentially the doctor-patient relationship:

252 *CP “The time that I have had patients really angry has been when I have been*  
 253 *reporting back uncertainty. They are in the middle of this situation where they are*  
 254 *trying to make a decision and I tell them something and then say “but I don’t know*  
 255 *what that means” and I have had really angry reactions” FG2*

256 However both groups also agreed that VUS should not be withheld:

257 *PRG “there is a tremendous pressure when they (CPs) are giving information for*  
 258 *which they can give no real certainty...but I would not want that to take away from*  
 259 *the autonomy of that woman from making a decision to end the pregnancy if that is*  
 260 *what they [she would] want because the potential we have at the moment is to*  
 261 *potentially be paternalistic about the information given because of what might be*  
 262 *done with it” FG1*

263 There was also consensus between the groups that VUS should be recorded in  
 264 databases to build up a picture of whether the variants are benign or pathological.

## 265 **Theme Six: Incidental findings and prenatal WES**

266 WES is capable of detecting ‘incidental findings’ which are mutations which can  
 267 sometimes associate with pathology. These findings are incidental because they are  
 268 unrelated to the reason for testing. Reporting incidental findings will have  
 269 implications for CPs’ time and healthcare resources, and there was a difference

270 between the views of CPs and PRGs. Some CPs felt that incidental findings should  
271 not be reported:

272 *CP “We don’t have a national screening program [to identify incidental findings] (for*  
273 *adults) so why are we doing screening by subterfuge [to detect such findings]*  
274 *through the fetus” FG2*

275 Other CPs discussed that there appears to be a progression to the reporting of  
276 incidental findings postnatally if there is treatment for the condition available.

277 PRGs highlighted the potential injury to the relationship between patients and  
278 medical professionals if an incidental result was revealed subsequently and it was  
279 felt this information had been withheld.

## 280 **Theme Seven: Access to prenatal WES information**

281 Both the PRGs and CPs agreed on the need for clear detailed written information to  
282 take away after the consultation. The PRGs suggested more detailed signposting or  
283 information sharing, particularly in relation to patient charities that could provide  
284 focused support to families. CPs also highlighted the need for national reporting  
285 guidance:

286 *CP “There should be some written information. Ideally in this day and age and*  
287 *definitely in 10 years there should be a dedicated website that they (parents) can*  
288 *access and find out information” FG2*

289 *CP “I think the ideal scenario would be to have national or even better international*  
290 *criteria for what is a definite [pathological variant] and what is a VUS and therefore*  
291 *you minimise the possibility [of uncertainty] for the parents” FG2*

292

## 293 **Conclusions**

294 All themes, with the exception of 'Analysis', were discussed by both CPs and PRGs.

295 Both groups generally had similar opinions. The process of consent for prenatal

296 WES was considered and concerns were raised regarding the current lack of clinical

297 geneticists/counsellors available to facilitate consent in prenatal clinical practice

298 within the UK National Healthcare System.

299 They also discussed the depth of the consent prior to the test, particularly when

300 taken under stressful circumstances. Previously authors have commented "*that it is*

301 *virtually impossible to counsel in these circumstances*"<sup>16</sup>. When pregnant women

302 find themselves in a stressful position, they may cope by complying with what they

303 believe is the health professional's recommendations<sup>17</sup>. It was generally agreed that

304 clinicians should do the best job possible pre-test but understand that the process

305 will not be perfect and that more detailed information should be provided to families

306 when genetic anomalies are found.

307 The issue of access to results was highlighted by the PRGs who felt that women

308 would want to know all information generated as it was '*their genome*'. PRGs also

309 felt that patients would ideally want reinterpretation of genetic information over time,

310 for instance if a VUS was recorded and was later found out to be pathological.

311 Conversely some CPs felt that interpretation should be performed at the point of

312 testing only and that on-going review was unsustainable. This is in contrast to the

313 views of Yu et al that propose "*results should be viewed as a dynamic, sustained*

314 *resource of information that is available to an individual not only at a single point in*  
315 *time, but over many years and even possibly a lifetime”<sup>18</sup>.*

316 It was felt that conveying uncertain information could create tension in the doctor  
317 patient relationship. In these circumstances patients require rapid follow up with a  
318 consultant clinical geneticist. Even when this has occurred people may make  
319 incorrect conclusions to fit with their own schemata<sup>12</sup>. Bernhardt et al interviewed  
320 women with VUS. Many of them considered uncertainty to be information that they  
321 wished they did not have (“toxic knowledge”)<sup>2</sup>. Women were left feeling anxious,  
322 and these concerns lingered into worries about their child’s development. This  
323 would be in opposition to recent research showing that patients consider all  
324 information very important<sup>19</sup>.

325 Some CPs felt that we should not report genes relating to adult onset conditions and  
326 allow the sequencing to become a screening test. However there has been  
327 progression towards reporting of adult onset conditions in the postnatal arena (as per  
328 guidance by the ACMG<sup>20</sup>) and it seems possible that this may transfer into the  
329 prenatal setting. Srebniak et al found that 55% of future parents want to be informed  
330 about adverse health effects at an adult stage but did not make a distinction between  
331 treatable and non treatable conditions<sup>21</sup>.

332 The potential contrast in views of the CPs and PRGs is also highlighted in the recent  
333 publication of views of nearly 7000 people on the return of incidental results from  
334 genetic sequencing<sup>22</sup>. Here compared with the public, genetic health professionals  
335 were five times more likely to think that incidental findings should not be returned.  
336 Participants were more interested in learning about conditions that were preventable  
337 and less interested in receiving information that is uncertain and cannot be



interpreted at the moment. It maybe that genetic health professionals anticipate a vast increase in workload with the seemingly rapid progression towards the use of sequencing in the prenatal and postnatal setting<sup>22</sup>. Recently Kalynchuk et al surveyed parental attitudes to WES and found that 83% felt it should be offered and 54% would potentially accept it. Only 2.2% were opposed to the testing. However over 70% reported an increased risk of adult onset conditions or a variant of uncertain significance would cause them anxiety<sup>23</sup>.

## **Limitations**

The number of focus group participants was limited by the number of CPs and PRGs who could be brought together geographically. Therefore this is a relatively small study. However it has been suggested that in qualitative work a small sample can provide useful information about participants' experience<sup>24</sup>. The number of focus groups we carried out accords with guidance for a 'small' study<sup>25</sup>, in which we were seeking information to inform further work and we did not aim or claim to reach data saturation<sup>26</sup>. We cannot comment on the extent to which the views expressed reflect those of CPs and PRGs as a whole, and further themes such may have arisen had we carried out further focus groups. There are a number of stakeholder groups involved in WES. This paper has presented the views of two such groups and although the patients' opinions themselves were not included in this study, we were able to gain useful insights into the topic area to inform further work to explore families' experiences. Using the themes which emerged from our focus groups a semi-structured interview has been designed and patients will be interviewed to determine their opinions on prenatal exome sequencing as part of the PAGE project

(<http://www.pageuk.org>). The opinions of obstetricians and gynaecologists, who are not specialists in fetal medicine, were not explored in this research and the perspectives of this particular group of clinical professionals may well have revealed some additional insights. There may also be details of significance that participants might have been willing to share more privately rather than in a focus group setting<sup>27</sup>. As private feedback was not sought from participants following the focus groups we are unable to comment on this, and as such the authors accept this as limiting aspect of this research.

It is premature to make concrete recommendations from these qualitative data but our findings suggest that consent in the prenatal arena is not a 'perfect' process. Consent-takers should be fully educated regarding the test. This work did not seek to fully explore the characterisation of the information that should be conveyed to make consent valid. We feel that further qualitative work needs to explore this and in particular capture the views of women and their families.

## References

1 Hillman SC, Pretlove S, Coomarasamy A, *et al*. Additional information from array comparative genomic hybridization technology over conventional karyotyping in prenatal diagnosis: a systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2011; 37:6-14.

- 382 2 Bernhardt BA, Soucier D, Hanson K, *et al.* Women's experiences receiving  
383 abnormal prenatal chromosomal microarray testing results. *Genet Med* 2013; 15:  
384 139-145.
- 385 3 Mardis ER. Next-generation DNA sequencing methods. *Annu Rev Genomics Hum*  
386 *Genet* 2008; 9:387-402.
- 387 4 Brandt DS, Shinkunas L, Hillis SL, *et al.* A closer look at the recommended criteria  
388 for disclosing genetic results: perspectives of medical genetic specialists, genomic  
389 researchers and institutional review board chairs. *J Genet Couns* 2013; 22:544-553.
- 390 5 Reiff M, Mueller R, Mulchandani S, *et al.* A qualitative study of healthcare  
391 providers' perspectives on the implications of genome-wide testing in paediatric  
392 clinical practice. *J Genet Couns* 2014; 23:474-488.
- 393 6 Bollinger JM, Scott J, Dvoskin R, *et al.* Public preferences regarding the return of  
394 individual genetic research results: findings from a qualitative focus group study.  
395 *Genet Med* 2012; 14:451-457.
- 396 7 Sapp JC, Dong D, Stark C, *et al.* Parental attitudes, values, and beliefs toward the  
397 return of results from exome sequencing in children. *Clin Genet* 2014; 85(2):120-  
398 126.
- 399 8 Bradbury AR, Patrick-Miller L, Egleston B. Parent opinions regarding the genetic  
400 testing of minors. *Genet Med* 2010; 28:3498-3505.

- 401 9 Levenseller BL, Soucier DJ, Miller VA, *et al.* Stakeholders' opinions on the  
402 implementation of paediatric whole exome sequencing: implications for informed  
403 consent. *J Genet Couns* 2014; 23:552-565.
- 404 10 Fisher A, Bonner C, Biankin AV, *et al.* Factors influencing intention to undergo  
405 whole genome screening in future healthcare: a single-blind parallel-group  
406 randomised trial. *Prev Med* 2012; 55:514-520.
- 407 11 Scully JL, Porz R, Rehmann-Sutter C. 'You don't make genetic test decisions  
408 from one day to the next' – using time to preserve moral space. *Bioethics* 2007; 21:  
409 208-217.
- 410 12 Hillman SC, Skelton J, Quinlan-Jones E, *et al.* 'If it helps...' The use of microarray  
411 technology in prenatal testing: patient and partners reflections. *Am J Med Genet A*  
412 2013; 161A:1619-1627.
- 413 13 Patton MQ. *Qualitative Evaluation and Research Methods* (2<sup>nd</sup> Edition) Newbury  
414 Park, California, Sage. 1990.
- 415 14 Ritchie J, Spencer L. Applied policy research (Ch 9) In: *Analyzing qualitative data*.  
416 London: Routledge. 1994:177-194.
- 417 15 Srivastava A, Thomson SB. Framework Analysis: A Qualitative Methodology for  
418 Applied Policy Research. *Journal of Administration and Governance* 2009; 4:72-79.

- 419 16 Vetro A, Bouman K, Hastings R, *et al.* The introduction of arrays in prenatal  
420 diagnosis: A special challenge. *Hum Mutat* 2012a; 33:923-9.
- 421 17 Aune I, Moller A, 'I want a choice, but I don't want to decide' a qualitative study of  
422 pregnant women's experiences regarding early ultrasound risk assessment for  
423 chromosomal anomalies. *Midwifery* 2012; 28:14-23.
- 424 18 Yu JH, Jamal SM, Tabor HK, *et al.* Self-guided management of exome and  
425 whole-genome sequencing results: changing the results return model. *Genet Med*  
426 2013; 15(9):684-90.
- 427 19 Waler SA, Kellom KS, Palmer SC, *et al.* Comparing genetic counselor's and  
428 patient's perceptions of needs in prenatal chromosomal testing. *Prenat Diagn*  
429 2015;35:870-878.
- 430 20 Green RC, Berg JS, Grody WW, *et al.* ACMG recommendations for reporting of  
431 incidental findings in clinical exome and genome sequencing. American College of  
432 Medical Genetics and Genomics. *Genet Med* 2013; 15:565-574.
- 433 21 Srebniak M, Boter M, Oudesluijs G, *et al.* Application of SNP array for rapid  
434 prenatal diagnosis: implementation, genetic counselling and diagnostic flow. *Eur J*  
435 *Hum Genet* 2011; 19:1230-7.
- 436 22 Middleton A, Morley KI, Bragin E, *et al.* Attitudes of nearly 7000 health  
437 professionals, genomic researchers and publics toward the return of incidental  
438 results from sequencing research. *Eur J Hum Genet* 2015; 24(1):21-29.

- 439 23 Kalynchuk EJ, Althouse A, Parker LS, *et al.* Prenatal whole-exome sequencing:  
440 parental attitudes. *Prenat Diagn* 2015; 35:1030-6.
- 441 24 Sandelowski M, Sample size in qualitative research. *Research in Nursing and*  
442 *Health* 1995; 18:179-183.
- 443 25 Braun V, Clark V. Successful qualitative research: A practical guide for beginners.  
444 London, Sage, 2013.
- 445 26 Baker SE, Edwards R. How many qualitative interviews is enough? Expert voices  
446 and early career reflections on sampling and cases in qualitative research. NCRM,  
447 National Centre for Research Methods Review Paper  
448 [eprints.ncrm.ac.uk/2273/4/how\\_many\\_interviews.pdf](http://eprints.ncrm.ac.uk/2273/4/how_many_interviews.pdf) [accessed on 12 April 2016].
- 449 27 Jayasekara RS, Focus groups in nursing research: Methodological perspectives.  
450 *Nursing Outlook* 2012; 60(6):411-416

451

452

453